ID   NCU-L-1
AC   CVCL_0G11
SY   NCU-L1; Nagoya City University-Leukemia-1
DR   Wikidata; Q54908292
RX   PubMed=19358282;
RX   PubMed=27457200;
CC   Population: Japanese.
CC   Virology: EBV-negative.
CC   Doubling time: 20-28 hours (PubMed=27457200).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C7954; Adult Burkitt leukemia
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 02-05-24; Version: 11
//
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
//
RX   PubMed=27457200; DOI=10.3109/10428199009050977;
RA   Nitta M., Iwaki O., Wakita A., Kodama H., Takeuchi G., Takada K.,
RA   Mitomo Y., Yamamoto M., Amano M., Murate T., Koike K., Osada H.,
RA   Ueda R., Shamoto M.;
RT   "A novel cell line (NCU-L-1) from a patient with acute lymphoblastic
RT   leukemia, FAB, L3, Burkitt's type.";
RL   Leuk. Lymphoma 3:67-71(1990).
//